TOP > 外国特許検索 > CHOLESTEROL-DEPENDENT CYTOLYSIN VARIANT AND USE THEREOF IN DDS

CHOLESTEROL-DEPENDENT CYTOLYSIN VARIANT AND USE THEREOF IN DDS

外国特許コード F120006881
整理番号 S2011-0448
掲載日 2012年9月26日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2012JP056203
国際公開番号 WO 2012121395
国際出願日 平成24年3月9日(2012.3.9)
国際公開日 平成24年9月13日(2012.9.13)
優先権データ
  • 特願2011-051295 (2011.3.9) JP
発明の名称 (英語) CHOLESTEROL-DEPENDENT CYTOLYSIN VARIANT AND USE THEREOF IN DDS
発明の概要(英語) The present invention provides a carrier whereby a drug capsule encapsulating a drug can be efficiently and very safely delivered to and incorporated into a variety of target cells or tissues, and also provides a drug delivery system in which the carrier is used. In the carrier, a cell- or tissue-specific antibody is bound to an antibody-binding domain of this cholesterol-dependent cytolysin variant. A cholesterol-containing microcapsule or functional cell packed with a medicinal ingredient or physiologically active substance serving as a carried material can be bound, via a domain (4) of the variant.
従来技術、競合技術の概要(英語) BACKGROUND ART
Worldwide in recent years, from the viewpoint of cancer patients is important QOL(Quality of Life), cancer surgery, systemic dosage of anticancer agents, radiation irradiation or the like other than the main stream of cancer therapy, immune cells and cancer therapy has been studied in a missile therapy. For this purpose and efficiently with a specific cancer cell targeting therapeutic drugs with fewer side effects acting on the development of tools has been desired. Cancer such as for example monoclonal antibodies used as a targeting molecule to the targeting technology for the development of anti-cancer linked to it and also to many investigations of being made. However, in practice, the target targeting molecules thereof in cancer cells in a large amount is not enough integrated technology, further improvement is necessary.
Also a number of viruses such as AIDS and hepatitis infection, congenital genetic disease or gene expression is further based on a malfunction such as illnesses are a significant problem in recent years. Or suppressing the development in the treatment of these diseases, suppression of gene expression or by the method of the RNAi, gene therapy for restoration of a particular gene can be applied, the future important in medicine has been a problem. Is the current drug deliver RNAi atelocollagen nonspecific carrier is used, gene therapy is generally put into practical use, targeted cells or tissues and organs selectively delivering the gene expression modulation becomes essential.
In view of these circumstances, conventionally, such as anti-cancer therapeutic drugs or gene therapy agent is encapsulated in a liposome at a high concentration, in an efficient and high safety is delivered to the target cells and tissues for the treatment of a disease in which the construction of drug delivery system (DDS) has been demanded.
In addition, a technique similar to the present invention as described above is disclosed, the present application are known in the prior literature, patent document 1, non-patent document 1 and 2 can be exemplified.
However, Patent Document 1 is, specifically recognizing the human cell membrane of the cell membrane binding domain N inter-media ricin Cys residues introduced at the terminus of the human cells specific binding can be found out, this characteristic is utilized to membrane-bound human cells as an adapter not merely proposes to use. The adapter comprises a membrane-bound human cells, human cells binds to the membrane a variety of materials useful for the compatibility with the immobilized, of the agent into the cell, no function of intracellular release of a second.
Non-patent document 1 is also, to the cell membrane by the technology described in the above-mentioned Patent Document 1 binding domain of the remaining Cys N inter-media ricin group was introduced into the end of the domain to 4, further anti-carcinoembryonic antigen (CEA) cancer which is coupled to the antibody, the positive human CEA such as medullary thyroid cancer cells can be cancer cells, for the treatment of cancer and can be applied to the present invention. This technique is, in the sense that it can target cancer cells is useful but, in the same manner as described in the patent document 1, a drug such as anticancer agent into the cell, intracellular release of a second effect cannot be expected.
Non-patent document 2 is further, cholesterol dependent cell lysis in the same manner as the present invention (cholesterol-dependent cytolysin toxin: CDC) using the drug delivery system is disclosed, by the introduction of a pore-forming ability binding SS controlled CDC (CDC-SS) variant N-terminus of a peptide having high affinity to lung carcinoma cells (lung cancer targeting domain) may be conjugated to a, specific drug delivery to lung carcinoma cells only during transport technology. That is, not only the specificity of lung cancer cells, the target variable because there is no general-purpose properties deteriorate.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • TOKUSHIMA UNIVERSITY
  • 発明者(英語)
  • NAGAMUNE, Hideaki
  • TOMOYASU, Toshifumi
  • TABATA, Atsushi
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT QA RO RS RU RW SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
ご興味のある方は、下記「問合せ先」へ電子メールまたはFAXでご連絡ください。

PAGE TOP

close
close
close
close
close
close